WOODCLIFF LAKE, N.J., May 22 /PRNewswire-FirstCall/ -- In an address to shareholders at the company's annual meeting, Medco Health Solutions, Inc. (NYSE: MHS) Chairman and CEO David B. Snow Jr. today underscored the accelerating momentum of key strategic drivers designed to deliver strong continuing earnings growth through 2008 and beyond -- initiatives ranging from generics, mail-order and specialty pharmacy to retaining and winning customers, and advanced clinical innovation.
"Without question, and by every measure, 2007 represented a breakthrough year for Medco and its shareholders as we surpassed every goal we had established across our business. We achieved a series of records in 2007, including record generic dispensing rate of 59.7 percent, and record mail-order dispensing volume of 94.8 million prescriptions," Snow said. "And we're off to a tremendous start in 2008, setting new sales records since becoming a public company, with $5.1 billion in annualized newnamed sales, $4.6 billion in net-new sales, and a 98 percent client retention rate. On top of all this, we are well underway in transforming the practice of pharmacy," Snow said.
"We are very proud of our 2007 and 2008 results. Our 2009 selling season is already off to a very strong start and we currently expect 2009 to represent another strong year for net-new sales. We look forward to sharing the details of our sales progress during our second quarter earnings call," reported Snow.
Medco Named "Most Admired"
Fortune magazine surveyed 622 companies across 64 industry sectors to
compile its list of 'America's Most Admired' Companies, and Medco was named
the single-most admired company in the category of Healthcare: Pharmacy and
Other Services. In ran
|SOURCE Medco Health Solutions, Inc.|
Copyright©2008 PR Newswire.
All rights reserved